PMID- 36284059
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221121
IS  - 2193-8210 (Print)
IS  - 2190-9172 (Electronic)
VI  - 12
IP  - 12
DP  - 2022 Dec
TI  - Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with 
      Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A 
      Real-World Evidence Study.
PG  - 2781-2795
LID - 10.1007/s13555-022-00831-w [doi]
AB  - INTRODUCTION: Chlormethine (CL) gel is a skin-directed therapy approved for 
      treatment of stage IA/IB mycosis fungoides-type cutaneous T-cell lymphoma 
      (MF-CTCL) in the USA. MF-CTCL has a chronic clinical course, requiring long-term 
      maintenance therapy with one or more therapies. This analysis describes 
      real-world patterns of maintenance therapy and use of concomitant therapy with CL 
      gel among patients with stage IA/IB MF-CTCL. METHODS: In a US-based registry, 
      MF-CTCL patients treated with CL gel were enrolled between 3/2015 and 10/2018 
      across 46 centers and followed for up to 2 years. Patient demographics, clinical 
      characteristics, CL gel treatment patterns, concomitant treatments, clinical 
      response, and adverse events (AEs) were collected from medical records. 
      Descriptive statistics are reported. RESULTS: Of the 206 patients with stage 
      IA/IB MF-CTCL, 58.7% were male, and average age was 60.7 years with 4.6 years 
      since diagnosis. Topical steroids, phototherapy, and topical retinoids were used 
      concomitantly with CL gel in 62.6%, 26.2%, and 6.3% of patients, respectively. 
      Most concomitant therapies (up to 85%) were started before CL gel initiation and, 
      in about half of the cases (up to 57%), were used concurrently for >/= 12 months. 
      Overall, 158 (76.7%) patients experienced partial response (PR) and 144 continued 
      with maintenance therapy. After achieving PR, most patients (74.3%) kept the same 
      maintenance therapy schedule, most commonly once daily. Of patients who had any 
      skin-related AE (31.6%) or skin-related AEs associated with CL gel (28.2%), 
      nearly half experienced CL gel treatment interruption and ~40% had a dosing 
      reduction. The observed real-world treatment patterns were concordant with 
      National Comprehensive Cancer Network (NCCN) guidelines. CONCLUSION: The study 
      results suggest that continuing CL gel maintenance therapy and combining 
      treatments with CL gel are common practice in the real-world setting, with most 
      maintained on a stable dosing schedule. Careful management of AEs may help 
      patients maintain long-term optimal dosing with less treatment interruptions and 
      dosing reductions.
CI  - (c) 2022. The Author(s).
FAU - Querfeld, Christiane
AU  - Querfeld C
AD  - City of Hope and Beckman Research Institute, 1500 E Duarte Rd, Duarte, CA, 91010, 
      USA.
FAU - Nelson, Winnie W
AU  - Nelson WW
AD  - Helsinn Therapeutics (U.S.), Inc., 170 Wood Avenue South, 5th Floor, Iselin, NJ, 
      08830, USA.
FAU - Gor, Deval
AU  - Gor D
AD  - Genesis Research, LLC., 111 River St, Suite 1120, Hoboken, NJ, 07030, USA.
FAU - Pashos, Chris L
AU  - Pashos CL
AD  - Genesis Research, LLC., 111 River St, Suite 1120, Hoboken, NJ, 07030, USA.
FAU - Doan, Quan V
AU  - Doan QV
AD  - Genesis Research, LLC., 111 River St, Suite 1120, Hoboken, NJ, 07030, USA.
FAU - Turini, Marco
AU  - Turini M
AD  - Helsinn Healthcare SA, Via Pian Scairolo 9, Lugano-Pazzallo, 6912, Lugano, 
      Switzerland.
FAU - Angello, James T
AU  - Angello JT
AD  - Helsinn Therapeutics (U.S.), Inc., 170 Wood Avenue South, 5th Floor, Iselin, NJ, 
      08830, USA.
FAU - Geskin, Larisa J
AU  - Geskin LJ
AD  - Department of Dermatology, Columbia University, 161 Fort Washington Ave, 12th 
      Floor, New York, NY, 10032, USA. ljg2145@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
DEP - 20221025
PL  - Switzerland
TA  - Dermatol Ther (Heidelb)
JT  - Dermatology and therapy
JID - 101590450
PMC - PMC9674809
OTO - NOTNLM
OT  - Chlormethine gel
OT  - MF-CTCL
OT  - Mechlorethamine gel
OT  - Mycosis fungoides-type cutaneous T-cell lymphoma
OT  - Real-world setting
OT  - Registry
OT  - Treatment patterns
EDAT- 2022/10/26 06:00
MHDA- 2022/10/26 06:01
PMCR- 2022/10/25
CRDT- 2022/10/25 23:18
PHST- 2022/08/25 00:00 [received]
PHST- 2022/10/04 00:00 [accepted]
PHST- 2022/10/26 06:00 [pubmed]
PHST- 2022/10/26 06:01 [medline]
PHST- 2022/10/25 23:18 [entrez]
PHST- 2022/10/25 00:00 [pmc-release]
AID - 10.1007/s13555-022-00831-w [pii]
AID - 831 [pii]
AID - 10.1007/s13555-022-00831-w [doi]
PST - ppublish
SO  - Dermatol Ther (Heidelb). 2022 Dec;12(12):2781-2795. doi: 
      10.1007/s13555-022-00831-w. Epub 2022 Oct 25.